Application of biomarker in screening and diagnosis of sexual precocity of children

A biomarker, children's technology, applied in the field of detection and analysis

Active Publication Date: 2021-10-29
上海血液生物医药有限责任公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, changes in endogenous sex hormones in the body usually occur at the same time as or after the appearance of secondary sexual characteristics. For example, in existing studies, reports have analyzed the feasibility of measuring serum sex hormones in diagnosing precocious puberty in children (see http: / / www. starlunwen.org / lunwen / 1423.html), but changes in endogenous sex hormones in the body are usually the result of precocious puberty, not the cause, so for children with precocious puberty, the clinic is very passive
Because the cause of precocious puberty in children has not been clearly reported, and there is no analysis and description of the early internal state before precocious puberty in children, such a situation results in that only when clinical secondary sexual characteristics appear prematurely in children Only when the child's precocious puberty can be discovered, but this time is too late

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker in screening and diagnosis of sexual precocity of children
  • Application of biomarker in screening and diagnosis of sexual precocity of children
  • Application of biomarker in screening and diagnosis of sexual precocity of children

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 138

[0040] Example 1 Determination of 58 Hormone Contents in Serum of 38 Children

[0041] The present embodiment provides a method for measuring the content of 58 hormones, the steps are as follows:

[0042] Step 1: Collect serum samples according to the standard method, store them at -80°C until the measurement, and thaw the samples before the measurement to prepare for the measurement;

[0043] Step 2: Take 250 microliters of serum samples, add 250 microliters of methanol, add 250 microliters of water, vortex centrifuge, and precipitate protein;

[0044] Step 3: Take 600 microliters of the supernatant and load the sample on the SPE plate (SPE plate model: Oasis PRiME HLBμElution 96plate);

[0045] Step 4: adding a mixed solution of acetonitrile / water (volume ratio 1:9) for elution, then adding 200 microliters of hexane for elution, and discarding the eluent;

[0046] Step 5: Add 30 microliters of methanol / acetonitrile (volume ratio 1:9) mixed solution, collect the eluent, add...

Embodiment 2

[0071] Determination of 58 hormone contents in the urine of 40 children in embodiment 2

[0072] The present embodiment provides a method for measuring the content of 58 hormones, the steps are as follows:

[0073] Step 1: Collect urine samples according to the standard method, store them at -80°C until the measurement, and thaw the samples before the measurement to prepare for the measurement;

[0074] Step 2: Take 0.5 ml of urine sample, add 0.25 ml of phosphate buffer, add 12.5 microliters of glucuronidase from Roman snail for enzymatic hydrolysis, incubate at 55°C for 1 hour, and cool to room temperature;

[0075] Step 3: Take 600 microliters of the supernatant and load the sample on the SPE plate (SPE plate model: Oasis PRiME HLBμElution 96plate);

[0076] Step 4: adding a mixed solution of acetonitrile / water (volume ratio 1:9) for elution, then adding 200 microliters of hexane for elution, and discarding the eluent;

[0077] Step 5: Add 30 microliters of methanol / aceto...

Embodiment 1

[0095] According to the results of Examples 1 and 2, the data in Tables 5 and 6 below are temporarily used as reference values ​​for judging children's precocious puberty. It should be noted that clinical normal values ​​generally need to follow the standard specifications established by international reference ranges, such as EP28-A3C Etc. usually need more than 1000-2000 samples, only the present data are used in the present invention to give reference values:

[0096] Table 5 Reference values ​​of serum samples for judging children's precocious puberty

[0097] Compound number Compound name Reference 15 hassinade 0.507735 31 Corticosterone 0.627328 32 cortisone 10.08267 33 Deoxycorticosterone 0.027505 34 Deoxycortisone 0.736734 38 17a-Hydroxyprogesterone 0.137664 45 Clobetasone Butyrate 2.691339 48 fludrocortisone acetate 0.646598 49 methylprednisolone acetate 0.304498 51 prednisolone acetate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a biomarker in preparation of a product for screening and diagnosing sexual precocity of children. The biomarker is prepared from one or more of halcinonide, corticosterone, cortisone, 11-deoxycorticosterone, 11-deoxycortisol, 17 alpha-hydroxyprogesterone, betasone butyrate, fludrocortisone acetate, methylprednisolone acetate, prednisolone acetate, hydrocortisone valerate, methyltestosterone and androstenedione (steroid). According to the application, a plurality of child samples are measured, and the result shows that specific compounds have significant difference between healthy children and precocious children, and the T test P value is less than 0.1, which shows that the contents of the compounds have significant difference. Therefore, the compounds with significant difference can be used as diagnostic markers for screening and diagnosing early sexual precocity of children.

Description

technical field [0001] The invention relates to the technical field of detection and analysis, in particular to the application of a biomarker in the screening and diagnosis of precocious puberty in children. Background technique [0002] Precocious puberty (PP) is an abnormal sexual development characterized by early sexual maturity. Research data at home and abroad in recent years have shown that the incidence of precocious puberty in children is on the rise. Precocious puberty has serious adverse effects on children's normal growth and development. Precocious puberty is often accompanied by advanced bone growth, which can easily lead to low height in adulthood. . In addition, studies have shown that the occurrence of precocious puberty in children is related to the occurrence of reproductive system malignancies. Precocious puberty has a significant impact on children's psychology and behavior, which may lead to negative emotions such as inferiority and isolation, and ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N30/02G01N30/06G01N30/14G01N30/34A61K45/00A61P15/08
CPCG01N30/02G01N30/06G01N30/14G01N30/34A61K45/00A61P15/08
Inventor 谭晓杰赵镇文郏征伟廖承慧徐永威
Owner 上海血液生物医药有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap